Table 1 Immunosuppression criteria and subgroups of interest.

From: Corticosteroids in immunocompromised ICU patients with severe COVID-19: a multicenter retrospective study

Corticosteroid therapy > 0.5 mg/kg/d prednisone equivalent and/or > 3 months (CORTICO)

Pathology or treatment leading to alteration of the monocyte contingent (MONO)

Large granular T-cell leukemia (LGL-T) and other causes of chronic neutropenia

Myelodysplastic syndrome

Acute myeloid leukemia

Hematopoietic stem cell allograft

Pathology or treatment leading to cellular immunodepression (CELL)

HIV with detectable viral load

Active cancer or < 5 years

T-lymphoid hemopathy (hairy cell leukemia, T-ALL, T-lymphoma, etc.)

Solid organ transplantation

Hematopoietic stem cell allograft

Connectivitis or vasculitis treated with immunosuppressants (mycophenolate mofetil, Endoxan, Azathioprine…)

Other treatments with Fludarabine, Ibrutinib, Alemtuzumab administered for an indication other than COVID

Pathology or treatment leading to humoral immunodepression (HUM)

B lymphoid hemopathy (CLL, lymphoma, myeloma, etc.)

Immunosuppressive treatments, in particular previous treatment with anti-CD20 monoclonal antibodies

Previous splenectomy

Functional asplenia with Jolly bodies on CBC (sickle cell disease, primary myelofibrosis, IBD, celiac disease, etc.)

Common variable immunodeficiency (CVID) and other causes of hypogammaglobulinemia or agammaglobulinemia

Deficiency of one or more proteins in the complement cascade (hemolytic uremic syndrome, paroxysmal nocturnal hemoglobinuria), treatment with anti-C5 administered for an indication other than COVID

Back to article page